Relationship of RUNX3 mRNA expression with clinicopathologic variables
| Variables . | Low RUNX3 expression (n = 22) . | High RUNX3 expression (n = 22) . | P . |
|---|---|---|---|
| Median age, y (range) | 8.5 (0.7-14) | 8.5 (0.7-17) | .882 |
| Sex, n (% males) | 9 (41) | 14 (64) | .131 |
| WBC, ×109/L, median (range) | 31 (2.6-295.7) | 14.2 (0.9-176) | .251 |
| t(8;21) or inv(16) translocation, n (%) | 11 (50) | 3 (14) | .010* |
| FAB subtypes, n (%) | .030* | ||
| M1 | 2 (9) | 5 (23) | |
| M2 / M4 | 13 (59) | 3 (14) | |
| M3 | 1 (5) | 5 (23) | |
| M5 | 2 (9) | 4 (18) | |
| M6 | 1 (5) | 0 (0) | |
| M7 | 3 (14) | 5 (23) | |
| FLT3 mutation, n (%) | 4 (18) | 4 (18) | 1.000 |
| Induction remission, n (%) | 22 (100) | 20 (91) | .148 |
| Relapse, n (%) | 3 (14) | 7 (35) | .104 |
| Death, n (%) | 4 (18) | 7 (32) | .296 |
| Variables . | Low RUNX3 expression (n = 22) . | High RUNX3 expression (n = 22) . | P . |
|---|---|---|---|
| Median age, y (range) | 8.5 (0.7-14) | 8.5 (0.7-17) | .882 |
| Sex, n (% males) | 9 (41) | 14 (64) | .131 |
| WBC, ×109/L, median (range) | 31 (2.6-295.7) | 14.2 (0.9-176) | .251 |
| t(8;21) or inv(16) translocation, n (%) | 11 (50) | 3 (14) | .010* |
| FAB subtypes, n (%) | .030* | ||
| M1 | 2 (9) | 5 (23) | |
| M2 / M4 | 13 (59) | 3 (14) | |
| M3 | 1 (5) | 5 (23) | |
| M5 | 2 (9) | 4 (18) | |
| M6 | 1 (5) | 0 (0) | |
| M7 | 3 (14) | 5 (23) | |
| FLT3 mutation, n (%) | 4 (18) | 4 (18) | 1.000 |
| Induction remission, n (%) | 22 (100) | 20 (91) | .148 |
| Relapse, n (%) | 3 (14) | 7 (35) | .104 |
| Death, n (%) | 4 (18) | 7 (32) | .296 |
WBC indicates white blood cell; FAB, French-American-British; and FLT3, Fms-like tyrosine kinase 3.
Statistically significant.